PURPOSE: To report a case of retinal toxicity following the administration of SBP-101 in combination with gemcitabine and nab-paclitaxel chemotherapy in a patient being treated for metastatic pancreatic ductal adenocarci...PURPOSE: To report a case of retinal toxicity following the administration of SBP-101 in combination with gemcitabine and nab-paclitaxel chemotherapy in a patient being treated for metastatic pancreatic ductal adenocarcinoma (PDAC). CASE REPORT: A 59-year-old woman diagnosed with metastatic pancreatic ductal adenocarcinoma was enrolled in a clinical trial involving SBP-101 combined with gemcitabine and nab-paclitaxel. Her ocular examination prior to chemotherapy and during treatment was unremarkable. However, four months after discontinuation of SBP-101, routine ophthalmic screening revealed atrophic changes in the outer retinal layers of both eyes, despite the absence of visual symptoms. The patient was subsequently monitored monthly, with progressive signs of retinal toxicity observed over time. CONCLUSION: While SBP-101 is under investigation for its potential in treating pancreatic cancer, this case highlights a significant concern regarding its ocular safety profile, particularly in relation to delayed-onset retinal toxicity. This case emphasizes the need for vigilance and long-term monitoring of patients receiving SBP-101-based therapies.
INTRODUCTION: Choroidal osteoma is a rare benign ocular tumor, with neovascular complications being even less common. The diagnosis is greatly facilitated by multimodal imaging techniques. However, treatment remains a ch...INTRODUCTION: Choroidal osteoma is a rare benign ocular tumor, with neovascular complications being even less common. The diagnosis is greatly facilitated by multimodal imaging techniques. However, treatment remains a challenge, as no standardized protocols exist, and current approaches rely primarily on intravitreal injections of anti-VEGF agents. CASE REPORT: We describe the case of a 45-year-old patient with no significant medical history who presented in 2020 with a progressive macular syndrome, characterized by decreased visual acuity and a central scotoma over several months. Ophthalmologic examination of the right eye was unremarkable, while the left eye showed reduced visual acuity of 3/10. The anterior segment was normal with a clear lens. Fundoscopy revealed a well-demarcated yellowish juxta-papillary subretinal lesion extending into the papillomacular area. Optical coherence tomography (OCT) demonstrated serous retinal detachment, intraretinal macular edema, and retinal pigment epithelial (RPE) detachments, along with a juxta-papillary eovascular membrane. A-scan ultrasonography confirmed the diagnosis of choroidal osteoma, showing a hyper-echogenic lesion with posterior shadowing. Retinal angiography and indocyanine green angiography (ICG) revealed occult neovascularization extending into the papillomacular area. The patient was treated with intravitreal anti-VEGF injections. Although the therapeutic response was gradual, injections every six weeks successfully maintained visual acuity at 7/10 and resolved the intra- and subretinal fluid. DISCUSSION AND CONCLUSION: The management of neovascular complications in choroidal osteoma remains complex due to the absence of standardized treatment protocols. Anti-VEGF therapy shows promise, albeit with a slow response, and requires sustained long-term administration to optimize visual outcomes and preserve visual function.
Posnic A, Vaast M, Poinas A
… +34 more, Le Pabic E, Bellamy JP, Delhay C, Faure S, Le Rouic JF, Henry A, Lebreton O, Masse H, Guillaumie T, Fournier I, Mainguy A, Le Lez ML, Khanna RK, George A, Pipelart V, Bernard Y, Grimbert P, Mazhar D, Benzerroug M, Briend B, Clement M, Jammes-Veaux HP, Posnic MP, Bonissent A, Guyot C, Rousseau N, Trinh Van Dam B, Bellot L, Ferron R, Le Meur G, Mouriaux F, Weber M, Maucourant Y, Ducloyer JB
PURPOSE: To assess whether switching to faricimab allowed extending injection intervals without exudation in patients with neovascular age-related macular degeneration (nAMD) and to identify predictive factors for interv...PURPOSE: To assess whether switching to faricimab allowed extending injection intervals without exudation in patients with neovascular age-related macular degeneration (nAMD) and to identify predictive factors for interval extension. METHODS: FAR WEST was a multicenter, observational retrospective cohort study, including patients with nAMD treated with intravitreal anti-VEGF injections (IVI) for at least one year prior to switching to faricimab. Data were collected from the medical records at the time of the decision to switch to faricimab (M0) and at the M6 follow-up visit. The switch strategy (whether an induction phase was performed or not) was left to the practitioner's discretion. RESULTS: A total of 814 eyes of 705 patients were included in 23 centers. The recurrence-free IVI interval increased significantly from 5.6 weeks at M0 to 7.2 weeks at M6 (+1.6 weeks, P<0.0001). The proportion of exudative patients decreased by 37% (P<0.0001). Among 228 refractory cases at M0, 88 (39%) achieved a dry macula at M6. A greater interval extension was found in patients who underwent immediate extension. No significant differences were observed in terms of age, time since first injection, type of neovascularisation, or pre-switch IVI interval. The intraocular inflammation rate was 0.6% (n=5). CONCLUSION: Switching to faricimab allowed for significantly extending the recurrence-free IVI interval and decreasing the proportion of exudative patients in this cohort. Significant extension was found in a wide range of patients, including those without a loading phase. Further controlled prospective studies are needed to assess the value of a loading phase when switching to faricimab. Safety outcomes were consistent with prior studies.
PURPOSE: To evaluate the effects of once daily latanoprostene bunod (LBN) and latanoprost (LP) on peripapillary optical coherence tomography angiography (OCTA) measurements in open angle glaucoma patients and to compare...PURPOSE: To evaluate the effects of once daily latanoprostene bunod (LBN) and latanoprost (LP) on peripapillary optical coherence tomography angiography (OCTA) measurements in open angle glaucoma patients and to compare the outcomes. METHODS: In this prospective, randomized clinical trial, Inclusion criteria were age 40years and older, open angle on gonioscopic examination, and intraocular pressure (IOP) ≥21mmHg with Goldmann applanation tonometry. All participants were divided into two groups by computer-based randomization: Vyzulta® (0.024% LBN, group 1) and Xalatan® (0.005% LP, group 2). Peripapillary OCTA imaging was performed before and one month into treatment. RESULTS: The IOP level measured in the first month of treatment was significantly lower in group 1 compared to group 2 (P<0.001). The mean IOP change (ΔIOP) was -34.4% in group 1 and -26.6% in group 2 (P<0.001). In the post-treatment period, the vessel density (VD) levels in the temporal quadrant (P=0.028) of the superficial slab, the inferior (P=0.029), nasal (P=0.005) and temporal quadrants (P=0.007) of the deep slab, and the inferior (P=0.014) and nasal (P=0.038) quadrants of the choriocapillaris slab were significantly higher in group 1 compared to group 2. CONCLUSIONS: In conclusion, LBN administered once a day increased VD in peripapillary OCTA. LP had no effect on VD. Future studies should be aimed at determining whether this effect of LBN is NO induced or due to higher IOP reduction.